REFERENCES:

1. Guindon J, et al. Cannabinoid CB2 receptors: a therapeutic target for neuropathic pain. Br J Pharmacol. 2007
2. Anthony AT, et al. Cannabinoid receptors and their association with chronic inflammatory pain. Cureus. 2020;
3. Guenther KG, et al. LY2828360, a cannabinoid CB2 agonist, suppresses neuropathic pain and reduces morphine tolerance in rats. Pharmocol Res. 2025;
4. Carey LM, et al. Peripheral sensory neuron CB2 cannabinoid receptors are analgesic in HIV-associated neuropathy. Neuropharmacology. 2023;
5. Pharmacotherapeutics role of Cannabinoid (CB1 & CB2) receptor agonists in chemotherapy-induced peripheral neuropathy: A Review. J Neonatal Surg. 2025
6. Racz IR et al., 2008 – Critical Role of the CB2 Cannabinoid Receptor in the Regulation of Central Immune Responses Leading to Neuropathic Pain. This landmark publication utilizes CB2 knockout and overexpressing mice to show CB2’s contribution to modulating glial activation and neuroinflammation following nerve injury and notably influencing neuropathic pain behaviors.
7. Guindon J et al., 2007 – Illustrates that selective CB2 agonists decrease neuropathic pain behaviors in rodent models without psychoactive CB1-related side effects, pointing to CB2 as an interesting analgesic target.
8. Ibrahim MM et al., 2003 – Demonstrated that CB2 receptor agonists decrease neuropathic pain through immune modulation, yielding early pharmacological evidence for therapeutic potential.
9. Romero-Sandoval EA et al., 2008 – Established CB2-mediated suppression of microglial activation and cytokine secretion, mechanisms responsible for the antinociceptive effects of CB2 agonists.
10. Maione S et al., 2007 – Investigated the role of endocannabinoid system modulation through FAAH inhibitors, evidencing tonic CB2 receptor activation in neuropathic pain management.
11.Klauke AL et al., 2014 – Utilized partial sciatic nerve ligation in wild-type and CB2 knockout mice to confirm the role of CB2 receptor in neuropathic pain modulation.
12.Cabral GA et al., 2008 – Discussed CB2 receptor expression in brain and spinal cord in neuropathic pain, with a focus on their contribution to central immune response.
13. Páldy E et al., 2008 – Defined new CB2 receptor agonists with slow signaling and showed their long-term anti-allodynic neuropathic pain and morphine tolerance suppression in rodents.
14. Anthony AT et al., 2020 – Evaluated CB2 receptor agonists in models of chemotherapy-induced neuropathy, validating anti-inflammatory and analgesic effects.
15. Guenther KG et al., 2025 – Outlined the efficacy of the CB2 agonist LY2828360 to diminish neuropathic pain and opioid tolerance, furthering clinical translation potential.
16. Carey LM et al., 2023 – Examined CB2 receptor activity in peripheral sensory neurons in HIV-associated neuropathy models with prominent analgesic effects.
17. Ehrhart J et al., 2005 – Showed that activation of the CB2 receptor suppresses microglial inflammatory responses.
18. Beltramo M et al., 2006 – Reported on CB2 agonists’ capacity to suppress neuropathic pain symptoms without CB1-associated side effects.
19. Puffenbarger RA et al., 2000 – Documented CB2 receptor-mediated decrease in inflammatory cytokine secretion by activated microglia.
20. Klegeris A et al., 2003 – Demonstrated CB2’s role in the modulation of neuroinflammation associated with pain.
21. Sheng WS et al., 2005 – Laid out the CB2 receptor agonists’ inhibition of microglial activation and neuronal excitotoxicity.
22. Maione S et al., 2019 – Examined synergistic analgesic properties of CB2 agonists with opioids to diminish morphine tolerance as well as opioid side effects.
23. Romero-Sandoval EA and Eisenach JC, 2007 – Investigated analgesic processes of CB2 receptor activation in neuropathic pain, including modulation of spinal glial.
24. Van Sickle MD et al., 2005 – Characterized CB2 receptor expression within neuronal and glial cell populations within CNS.
25. Di Marzo V, 1998 – Emphasized the on-demand synthesis and regulation of endocannabinoids responsible for activation of CB2 receptors following nerve injury.
26. Agarwal N et al., 2007 – Reported elevated levels of endocannabinoids following nerve injury in peripheral and central nervous system.
27. Ofek O et al., 2006 – Demonstrated pharmacological characterization of CB2 receptor-deficient mice and their modified pain sensitivity.
28. Buckley NE et al., 2000 – Genetic research showing CB2 receptor functions in immune cell function linked to neuropathic pain.
29. Petrosino S et al., 2007 – Documented the increase of endocannabinoid concentration within brain regions linked with pain modulation.
30. Maione S et al., 2007 – Demonstrated that inhibition of FAAH increases endocannabinoid levels lowering neuropathic pain through CB2 receptors.
31. Pharmacotherapeutic reviews, 2025 – Summarized recent developments in CB2 selective agonists in chemotherapy-induced neuropathy.
32. Preclinical research demonstrating lack of central psychotropic effects with CB2 agonists (multiple authors).
33. Research describing molecular mechanisms (MAPK, cytokine modulation) through which CB2 activation suppresses neuroinflammation and pain sensitization.
34. Research on bone marrow chimera models demonstrating hematopoietic cell CB2 receptor involvement in neuropathic pain (Racz IR et al., 2008).
35. Reviews of CB2 receptor agonists’ safety profile and suitability for chronic pain therapy without addictive liability.